STOK Phase III Dravet and sustained seizure reduction support milestones
STOK says a phase III Dravet syndrome readout is expected within 12 months and progress continues in ADOA trials. Zorevunersen reports sustained 75% seizure reduction plus functional gains, with OLE data supporting long-term efficacy.
Key milestones include a phase III readout for Dravet syndrome within 12 months, along with progress in ADOA trials. Zorevunersen has shown sustained 75% seizure reduction and functional gains, while open-label extension data support long-term efficacy. The EMPEROR study is well-powered, and the commercial strategy leverages rob…